WallStSmart

Fresenius Medical Care Corporation (FMS)vsMednax Inc (MD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Fresenius Medical Care Corporation generates 926% more annual revenue ($19.63B vs $1.91B). MD leads profitability with a 8.6% profit margin vs 5.0%. MD appears more attractively valued with a PEG of 0.24. MD earns a higher WallStSmart Score of 67/100 (B-).

FMS

Buy

62

out of 100

Grade: C+

Growth: 5.3Profit: 5.0Value: 10.0Quality: 7.0
Piotroski: 6/9Altman Z: 1.82

MD

Strong Buy

67

out of 100

Grade: B-

Growth: 3.3Profit: 6.5Value: 10.0Quality: 7.0
Piotroski: 5/9Altman Z: 1.56
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

FMSUndervalued (+73.4%)

Margin of Safety

+73.4%

Fair Value

$90.32

Current Price

$22.03

$68.29 discount

UndervaluedFair: $90.32Overvalued
MDUndervalued (+55.8%)

Margin of Safety

+55.8%

Fair Value

$48.58

Current Price

$21.19

$27.39 discount

UndervaluedFair: $48.58Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

FMS3 strengths · Avg: 9.3/10
P/E RatioValuation
11.2x10/10

Attractively priced relative to earnings

Price/BookValuation
0.4x10/10

Reasonable price relative to book value

PEG RatioValuation
0.738/10

Growing faster than its price suggests

MD4 strengths · Avg: 9.3/10
PEG RatioValuation
0.2410/10

Growing faster than its price suggests

P/E RatioValuation
10.9x10/10

Attractively priced relative to earnings

Return on EquityProfitability
20.3%9/10

Every $100 of equity generates 20 in profit

Price/BookValuation
2.0x8/10

Reasonable price relative to book value

Areas to Watch

FMS4 concerns · Avg: 3.5/10
EPS GrowthGrowth
4.2%4/10

4.2% earnings growth

Altman Z-ScoreHealth
1.824/10

Grey zone — moderate risk

Return on EquityProfitability
7.9%3/10

ROE of 7.9% — below average capital efficiency

Profit MarginProfitability
5.0%3/10

5.0% margin — thin

MD3 concerns · Avg: 3.0/10
Altman Z-ScoreHealth
1.564/10

Distress zone — elevated risk

Market CapQuality
$1.82B3/10

Smaller company, higher risk/reward

Revenue GrowthGrowth
-1.7%2/10

Revenue declined 1.7%

Comparative Analysis Report

WallStSmart Research

Bull Case : FMS

The strongest argument for FMS centers on P/E Ratio, Price/Book, PEG Ratio. PEG of 0.73 suggests the stock is reasonably priced for its growth.

Bull Case : MD

The strongest argument for MD centers on PEG Ratio, P/E Ratio, Return on Equity. PEG of 0.24 suggests the stock is reasonably priced for its growth.

Bear Case : FMS

The primary concerns for FMS are EPS Growth, Altman Z-Score, Return on Equity. Thin 5.0% margins leave little buffer for downturns.

Bear Case : MD

The primary concerns for MD are Altman Z-Score, Market Cap, Revenue Growth.

Key Dynamics to Monitor

FMS carries more volatility with a beta of 0.94 — expect wider price swings.

FMS is growing revenue faster at -0.3% — sustainability is the question.

FMS generates stronger free cash flow (564M), providing more financial flexibility.

Monitor MEDICAL CARE FACILITIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

MD scores higher overall (67/100 vs 62/100). FMS offers better value entry with a 73.4% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Fresenius Medical Care Corporation

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America and internationally. The company is headquartered in Bad Homburg, Germany.

Visit Website →

Mednax Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

MEDNAX, Inc., provides neonatal, maternal-fetal, pediatric cardiology, and other pediatric subspecialties in the United States and Puerto Rico. The company is headquartered in Sunrise, Florida.

Visit Website →

Want to dig deeper into these stocks?